Journal ArticleDOI
4. Modelling Survival Data in Medical Research
About:
This article is published in Journal of The Royal Statistical Society Series A-statistics in Society.The article was published on 1995-01-01. It has received 1092 citations till now. The article focuses on the topics: Medical research.read more
Citations
More filters
Journal ArticleDOI
Mineral Metabolism, Mortality, and Morbidity in Maintenance Hemodialysis
Geoffrey A. Block,Preston S. Klassen,J. Michael Lazarus,Norma J. Ofsthun,Edmund G. Lowrie,Glenn M. Chertow +5 more
TL;DR: Hyperphosphatemia and hyperparathyroidism were significantly associated with all-cause, cardiovascular, and fracture-related hospitalization, and the population attributable risk percentage for disorders of mineral metabolism was 17.5%, owing largely to the high prevalence of hyperph phosphatemia.
Journal ArticleDOI
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Robert J. Motzer,Thomas E. Hutson,Piotr Tomczak,M. Dror Michaelson,Ronald M. Bukowski,Stéphane Oudard,Sylvie Negrier,Cezary Szczylik,Roberto Pili,Georg A. Bjarnason,Xavier Garcia-del-Muro,Jeffrey A. Sosman,Ewa Solska,George Wilding,John A. Thompson,Sindy T. Kim,Isan Chen,Xin Huang,Robert A. Figlin +18 more
TL;DR: Sunitinib demonstrates longer overall survival compared with IFN-alpha plus improvement in response and progression-free survival in the first-line treatment of patients with metastatic RCC, highlighting an improved prognosis in patients with RCC in the era of targeted therapy.
Journal ArticleDOI
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Ignace Vergote,Claes G. Tropé,Frédéric Amant,G.B. Kristensen,Tom Ehlen,N Johnson,René H.M. Verheijen,Maria E. L. van der Burg,A. J. Lacave,Pierluigi Benedetti Panici,Gemma G. Kenter,Antonio Casado,Cesar Mendiola,Corneel Coens,Leen Verleye,Gavin Stuart,Sergio Pecorelli,Nicholas Reed +17 more
TL;DR: Neoadjuvant chemotherapy followed by interval debulking surgery was not inferior to primary debulked surgery followed by chemotherapy as a treatment option for patients with bulky stage IIIC or IV ovarian carcinoma in this study.
Journal ArticleDOI
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
TL;DR: Five prognostic factors for predicting survival were identified and used to categorize patients with metastatic RCC into three risk groups, for which the median survival times were separated by 6 months or more.
References
More filters
Journal ArticleDOI
CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
TL;DR: It is concluded that elderly patients with aggressive CD20-positive lymphoma show a significantly lower incidence of CNS disease if treated with R-CHop-14 instead of CHOP-14, with the possible exception of patients with testicular involvement.
Journal ArticleDOI
Patient Age and Decisions To Withhold Life-Sustaining Treatments from Seriously Ill, Hospitalized Adults
Mary Beth Hamel,Joan M. Teno,Lee Goldman,Joanne Lynn,Roger B. Davis,Anthony N. Galanos,Norman A. Desbiens,Alfred F. Connors,Neil S. Wenger,Russell S. Phillips +9 more
TL;DR: This study studied 9105 seriously ill patients to evaluate how patient age, independent of patients' objective prognoses and preferences for life-extending care, influences physicians' decisions to withhold life-sustaining therapies.
Journal ArticleDOI
Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD: Searching for the Best Risk Marker by Multivariate Modeling
TL;DR: IL-6 adds significantly greater predictive power for all-cause and CV death to statistical models based on traditional and nontraditional risk factors in ESRD patients, and the risk estimate by CRP being reasonably close to that of IL-6, CRP may be a cheap alternative to IL- 6 in clinical practice.
Journal ArticleDOI
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Bradley J. Monk,Andrés Poveda,Ignace Vergote,Francesco Raspagliesi,Keiichi Fujiwara,Duk-Soo Bae,Ana Oaknin,Isabelle Ray-Coquard,Diane Provencher,Beth Y. Karlan,Catherine Lhommé,Gary Richardson,Dolores Gallardo Rincón,Robert L. Coleman,Thomas J. Herzog,Christian Marth,Arija Brize,Michel Fabbro,Andrés Redondo,Aristotelis Bamias,Marjan Tassoudji,Lynn Navale,Douglas Warner,Amit M. Oza +23 more
TL;DR: Inhibition of angiopoietins 1 and 2 with trebananib provided a clinically meaningful prolongation in progression-free survival, and this non-VEGF anti-angiogenesis option for women with recurrent epithelial ovarian cancer should be investigated in other settings and in combination with additional agents.
Journal ArticleDOI
Survival dynamics of scleractinian coral larvae and implications for dispersal
TL;DR: Results show how variation in larval survivorship with age may help to explain the seeming paradox of high genetic structure at metapopulation scales, coupled with the maintenance of extensive geographic ranges observed in many coral species.